Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KMO | O15229 | 8/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301472 | 0.94 | KMO (0.57) | HSD17B1HSD17B2MEN1KMT2AKMO | |
| SCHEMBL31301616 | 0.94 | KMO (0.57) | HSD17B1HSD17B2MEN1KMT2AKMO | |
| SCHEMBL31301328 | 0.87 | KMO (0.62) | MEN1KMT2AKMOGPBAR1GRM1 | |
| SCHEMBL31301337 | 0.81 | KMO (0.54) | MEN1KMT2AKMOGPBAR1 | |
| SCHEMBL31301385 | 0.80 | KMO (0.53) | MEN1KMT2AKMOGPBAR1SMN1; SMN2 | |
| SCHEMBL31301462 | 0.79 | GPBAR1 (0.53) | MEN1KMT2AKMOGPBAR1 | |
| SCHEMBL31301427 | 0.79 | KMO (0.71) | MEN1KMT2AKMOSMN1; SMN2 | |
| SCHEMBL28048743 | 0.79 | KMO (0.71) | MEN1KMT2AKMOSMN1; SMN2 | |
| SCHEMBL28048792 | 0.77 | MEN1 (0.53) | MEN1KMT2AKMOSMN1; SMN2KDM4E | |
| SCHEMBL28048742 | 0.77 | KMO (0.55) | MEN1KMT2AKMOSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | HSD17B1 1543/4885HSD17B2 1780/4885MEN1 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.